Barry J. Simon - 24 Feb 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Director
Signature
/s/ Philip LoScalzo, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
24 Feb 2026
Net transactions value
-$900,788
Form type
4
Filing time
26 Feb 2026, 20:12:26 UTC
Previous filing
24 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Simon Barry J. Director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO /s/ Philip LoScalzo, as Attorney-in-Fact 26 Feb 2026 0001647994

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Sale $900,788 -75,000 -2.6% $12.01* 2,850,821 24 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.
F2 Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $12.00 to $12.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.